Jindike released its 2026 semi-annual report, showing a net loss attributable to shareholders of about 51.07 million yuan in the first half, compared with a loss of about 39.65 million yuan in the same period last year. The company achieved operating revenue of about 910,900 yuan in the first half, down 74.15 percent year on year. Jindike focuses on the research, development, production and sales of human vaccines, with main products including 10 human vaccine products targeting five infectious diseases: influenza, rabies, chickenpox, shingles and pneumonia. The company said the decline in operating revenue was mainly due to lower sales volume during the reporting period.
Jiangsu GDK Biotechnology Co LtdFirst-half net loss widened to 51.07 million yuan with revenue down 74.15% year on year.
